Floatz logo

Ipilimumab

Iris Melanoma

Case Comprehensive Cancer Centermonoclonal_antibodyEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Iris Melanoma cohort.

Asset / SponsorPhaseRating
Tyrosinase Peptide
National Cancer Institute (NCI)
Phase 3BB
Sargramostim
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
H. Lee Moffitt Cancer Center and Research Institute
Phase 2B
DACARBAZINE
National Cancer Institute (NCI)
Phase 2B
gp100 antigen
National Cancer Institute (NCI)
Phase 2B

View all 23 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →